BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, McCashland TM, Hoteit MA, Shaked A, Saab S, Chi AC, Tien A, Schiano TD. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142:1132-1139.e1. [PMID: 22285805 DOI: 10.1053/j.gastro.2012.01.030] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Stock PG, Terrault NA. Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology 2015;61:1747-54. [PMID: 25292153 DOI: 10.1002/hep.27553] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
2 Londoño MC, Crespo G, Forns X. Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Curr Opin Organ Transplant 2013;18:271-8. [PMID: 23665543 DOI: 10.1097/MOT.0b013e3283614aca] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Ueda Y, Ikegami T, Soyama A, Akamatsu N, Shinoda M, Ishiyama K, Honda M, Marubashi S, Okajima H, Yoshizumi T, Eguchi S, Kokudo N, Kitagawa Y, Ohdan H, Inomata Y, Nagano H, Shirabe K, Uemoto S, Maehara Y. Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience: Simeprevir-based triple therapy after LDLT. Hepatol Res 2016;46:1285-93. [DOI: 10.1111/hepr.12684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
4 Ho CM, Hu RH, Lee PH. Perspective of antiviral therapeutics for hepatitis C after liver transplantation. World J Pharmacol 2014; 3(4): 193-198 [DOI: 10.5497/wjp.v3.i4.193] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 2020;50:791-816. [PMID: 32343477 DOI: 10.1111/hepr.13503] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
6 Jung J, Kwon JH, Song GW, Tak EY, Kirchner VA, Lee SG. Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents. J Gastrointest Surg 2018;22:1334-42. [PMID: 29679347 DOI: 10.1007/s11605-018-3779-9] [Reference Citation Analysis]
7 Little EC, Berenguer M. The New Era of Hepatitis C: Therapy in Liver Transplant Recipients. Clin Liver Dis 2017;21:421-34. [PMID: 28364822 DOI: 10.1016/j.cld.2016.12.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mirjalili M, Shafiekhani M, Vazin A. Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. Ther Clin Risk Manag 2020;16:617-29. [PMID: 32694915 DOI: 10.2147/TCRM.S256246] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
9 Weiler N, Zeuzem S, Welker MW. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol 2016; 22(41): 9044-9056 [PMID: 27895394 DOI: 10.3748/wjg.v22.i41.9044] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Campos-Varela I, Agudelo EZ, Terrault NA. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series. Clin Transplant 2018;32:e13303. [PMID: 29851150 DOI: 10.1111/ctr.13303] [Reference Citation Analysis]
11 Agarwal K, Barnabas A. Treatment of chronic hepatitis C virus infection after liver transplantation. Dig Liver Dis. 2013;45 Suppl 5:S349-S354. [PMID: 24091115 DOI: 10.1016/j.dld.2013.07.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58:1028-1041. [PMID: 23262248 DOI: 10.1016/j.jhep.2012.12.014] [Cited by in Crossref: 104] [Cited by in F6Publishing: 88] [Article Influence: 10.4] [Reference Citation Analysis]
13 Singaravelu R, Nasheri N, Sherratt A, Pezacki JP. Systems biology methods help develop a better understanding of hepatitis C virus-induced liver injury. Hepatology 2012;56:1-4. [DOI: 10.1002/hep.25727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Orita N, Shimakami T, Sunagozaka H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Takatori H, Kawaguchi K, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clin J Gastroenterol 2019;12:63-70. [PMID: 29995231 DOI: 10.1007/s12328-018-0884-y] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Bixby AL, Fitzgerald L, Leek R, Mellinger J, Sharma P, Tischer S. Impact of direct-acting antivirals for hepatitis C virus therapy on tacrolimus dosing in liver transplant recipients. Transpl Infect Dis. 2019;21:e13078. [PMID: 30884055 DOI: 10.1111/tid.13078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Vukotic R, Vitale G, D’Errico-Grigioni A, Muratori L, Andreone P. De novo autoimmune hepatitis in liver transplant: State-of-the-art review. World J Gastroenterol 2016; 22(10): 2906-2914 [PMID: 26973387 DOI: 10.3748/wjg.v22.i10.2906] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
17 Nojoomi A, Tamjid E, Simchi A, Bonakdar S, Stroeve P. Injectable polyethylene glycol-laponite composite hydrogels as articular cartilage scaffolds with superior mechanical and rheological properties. International Journal of Polymeric Materials and Polymeric Biomaterials 2016;66:105-14. [DOI: 10.1080/00914037.2016.1182914] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
18 Patwardhan VR, Curry MP. Reappraisal of the hepatitis C virus-positive donor in solid organ transplantation. Curr Opin Organ Transplant. 2015;20:267-275. [PMID: 25944236 DOI: 10.1097/mot.0000000000000191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Åberg F, Nordin A, Toivonen L, Isoniemi H. Early Predictors of Long-term Outcomes of HCV-negative Liver Transplant Recipients Having Survived the First Postoperative Year. Transplantation 2016;100:382-90. [PMID: 26683515 DOI: 10.1097/TP.0000000000001038] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Saab S, Greenberg A, Li E, Bau SN, Durazo F, El-Kabany M, Han S, Busuttil RW. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015;35:2442-2447. [PMID: 25913321 DOI: 10.1111/liv.12856] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
21 Takeishi K, Ikegami T, Yoshizumi T, Itoh S, Harimoto N, Harada N, Tsujita E, Kimura Y, Yamashita Y, Saeki K, Oki E, Shirabe K, Maehara Y. Thymoglobulin for steroid-resistant immune-mediated graft dysfunction during simeprevir-based antiviral treatment for post-transplantation hepatitis C: case report. Transplant Proc 2015;47:794-5. [PMID: 25891734 DOI: 10.1016/j.transproceed.2014.11.056] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Sharma P, Hosmer A, Appelman H, McKenna B, Jafri MS, Sullivan P, Fontana RJ, Lok AS. Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival. Hepatol Int 2013;7:990-9. [PMID: 25815091 DOI: 10.1007/s12072-013-9436-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
23 Ikegami T, Yoshizumi T, Shirabe K, Maehara Y. Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation. J Hepatol. 2014;60:894-896. [PMID: 24316026 DOI: 10.1016/j.jhep.2013.10.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
24 White SL, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, Chadban S, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplant Direct 2019;5:e416. [PMID: 30656214 DOI: 10.1097/TXD.0000000000000852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
25 Ueda Y, Yoshizawa A, Ogura Y, Miyagawa-Hayashino A, Haga H, Chiba T, Uemoto S. Plasma cell hepatitis induced by the termination of antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res 2014;44:E279-83. [PMID: 24112365 DOI: 10.1111/hepr.12243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Noell BC, Besur SV, deLemos AS. Changing the face of hepatitis C management - the design and development of sofosbuvir. Drug Des Devel Ther. 2015;9:2367-2374. [PMID: 25987834 DOI: 10.2147/dddt.s65255] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
27 Suda G, Ogawa K, Morikawa K, Sakamoto N. Treatment of hepatitis C in special populations. J Gastroenterol 2018;53:591-605. [PMID: 29299684 DOI: 10.1007/s00535-017-1427-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
28 Zhang JY, Li YY, Zhang Z, Wang FS. The prediction of immunological dysfunction during antiviral therapy for HCV after liver transplantation: can we improve outcomes? Hepatol Int 2013;7:948-50. [PMID: 26202024 DOI: 10.1007/s12072-013-9474-8] [Reference Citation Analysis]
29 Beckebaum S, Kabar I, Cicinnati VR. Hepatitis B and C in liver transplantation: new strategies to combat the enemies. Rev Med Virol 2013;23:172-93. [PMID: 23239274 DOI: 10.1002/rmv.1734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Marjot T, Webb GJ, Barritt AS 4th, Moon AM, Stamataki Z, Wong VW, Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol 2021;18:348-64. [PMID: 33692570 DOI: 10.1038/s41575-021-00426-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
31 Rodríguez-medina B, Blanes M, Vinaixa C, Aguilera V, Rubín Á, Prieto M, Berenguer M. Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. Annals of Hepatology 2013;12:974-8. [DOI: 10.1016/s1665-2681(19)31305-5] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
32 Chan C, Schiano T, Agudelo E, Paul Haydek J, Hoteit M, Laurito MP, Norvell JP, Terrault N, Verna EC, Yang A, Levitsky J. Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. Am J Transplant. 2018;18:2506-2512. [PMID: 30075485 DOI: 10.1111/ajt.15053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
33 Gane E. Liver Transplantation for Chronic Hepatitis B and C. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 203-17. [DOI: 10.1002/9781118637272.ch15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl. 2012;18:1053-1059. [PMID: 22706796 DOI: 10.1002/lt.23482] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
35 Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531-548. [PMID: 23199510 DOI: 10.1016/j.bpg.2012.09.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
36 Naini BV, Lassman CR. Liver Transplant Pathology: Review of Challenging Diagnostic Situations. Surg Pathol Clin 2013;6:277-93. [PMID: 26838975 DOI: 10.1016/j.path.2013.03.004] [Reference Citation Analysis]
37 Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601-1605. [PMID: 23593993 DOI: 10.1111/ajt.12209] [Cited by in Crossref: 110] [Cited by in F6Publishing: 99] [Article Influence: 12.2] [Reference Citation Analysis]
38 Ikegami T, Shirabe K, Yoshizumi T, Furusyo N, Kotoh K, Kato M, Shimoda S, Soejima Y, Motomura T, Fukuhara T. Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation. Transplantation. 2013;95:e38-e42. [PMID: 23507656 DOI: 10.1097/tp.0b013e318283a82e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Russo MW, Narang T, Eskind L, Hayes D, Casingal V, Purdum PP, Hanson JS, Ahrens W, Norton J, Bonkovsky H. Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection. Dig Dis Sci 2013;58:3010-6. [PMID: 23812862 DOI: 10.1007/s10620-013-2749-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Kerkar N, Yanni G. ‘De novo’ and ‘recurrent’ autoimmune hepatitis after liver transplantation: A comprehensive review. Journal of Autoimmunity 2016;66:17-24. [DOI: 10.1016/j.jaut.2015.08.017] [Cited by in Crossref: 58] [Cited by in F6Publishing: 40] [Article Influence: 9.7] [Reference Citation Analysis]
41 Kallwitz ER. Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy. World J Gastroenterol 2013; 19(2): 158-160 [PMID: 23345937 DOI: 10.3748/wjg.v19.i2.158] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
43 Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014;60:872-84. [PMID: 24280292 DOI: 10.1016/j.jhep.2013.11.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
44 Joshi D, Carey I, Agarwal K. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Aliment Pharmacol Ther. 2013;37:659-671. [PMID: 23432320 DOI: 10.1111/apt.12260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
45 Kwon J, Hanouneh I, Allende D, Yerian L, Diago T, Eghtesad B, Zein N. De Novo Autoimmune Hepatitis Following Liver Transplantation. Transplantation Proceedings 2018;50:1451-6. [DOI: 10.1016/j.transproceed.2018.02.066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Aguilera V. Hepatitis C virus recurrence after liver transplantation: how to treat and when. Transplant Proc 2014;46:3100-3. [PMID: 25420834 DOI: 10.1016/j.transproceed.2014.09.177] [Reference Citation Analysis]
47 Rendina M, D'Amato M, Castellaneta A, Castellaneta NM, Brambilla N, Giacovelli G, Rovati L, Rizzi SF, Zappimbulso M, Bringiotti RS, Di Leo A. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial. Transpl Int 2014;27:696-704. [PMID: 24673819 DOI: 10.1111/tri.12324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
48 Vasuri F, Malvi D, Gruppioni E, Grigioni WF, D’Errico-Grigioni A. Histopathological evaluation of recurrent hepatitis C after liver transplantation: A review. World J Gastroenterol 2014; 20(11): 2810-2824 [PMID: 24659874 DOI: 10.3748/wjg.v20.i11.2810] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
49 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 52.0] [Reference Citation Analysis]
50 Saab S, Rheem J, Jimenez M, Bau S, Choi G, Durazo F, El Kabany M, Han S, Farid A, Jamal N, Grotts J, Elashoff D, Busuttil RW. Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. J Clin Transl Hepatol 2016;4:32-8. [PMID: 27047770 DOI: 10.14218/JCTH.2016.00001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
51 Demetris AJ, Bellamy C, Hübscher SG, O’Leary J, Randhawa PS, Feng S, Neil D, Colvin RB, McCaughan G, Fung JJ. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016; Epub ahead of print. [PMID: 27273869 DOI: 10.1111/ajt.13909] [Cited by in Crossref: 230] [Cited by in F6Publishing: 187] [Article Influence: 38.3] [Reference Citation Analysis]
52 Ueda Y, Uemoto S. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients. Transplantation 2016;100:54-60. [PMID: 26335914 DOI: 10.1097/TP.0000000000000860] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
53 Sheen V, Nguyen H, Jimenez M, Agopian V, Vangala S, Elashoff D, Saab S. Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. J Clin Transl Hepatol 2016;4:20-5. [PMID: 27047768 DOI: 10.14218/JCTH.2015.00034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Ikegami T, Wang H, Yoshizumi T, Toshima T, Aishima S, Fukuhara T, Furusyo N, Kotoh K, Shimoda S, Shirabe K, Maehara Y. Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C. Hepatol Int 2014;8:285-92. [DOI: 10.1007/s12072-013-9496-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
55 Durand F, Francoz C. The future of liver transplantation for viral hepatitis. Liver Int 2017;37:130-5. [DOI: 10.1111/liv.13310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
56 Harrington CR, Yang GY, Levitsky J. Advances in Rejection Management: Prevention and Treatment. Clin Liver Dis 2021;25:53-72. [PMID: 33978583 DOI: 10.1016/j.cld.2020.08.003] [Reference Citation Analysis]
57 Ikegami T, Yoshizumi T, Yoshida Y, Kurihara T, Harimoto N, Itoh S, Shimokawa M, Fukuhara T, Shirabe K, Maehara Y. Telaprevir versus simeprevir for the treatment of recurrent hepatitis C after living donor liver transplantation. Hepatol Res 2016;46:E136-45. [PMID: 26096514 DOI: 10.1111/hepr.12546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
58 Ikegami T, Yoshizumi T, Kato M, Yamamoto S, Fukuhara T, Matsuura Y, Nakamura S, Itoh S, Shirabe K, Maehara Y. Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Transplantation 2014;98:994-9. [PMID: 25099704 DOI: 10.1097/TP.0000000000000166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplantation: Viral Hepatitis. American Journal of Transplantation 2013;13:147-68. [DOI: 10.1111/ajt.12108] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 6.2] [Reference Citation Analysis]
60 deLemos AS, Schmeltzer PA, Russo MW. Recurrent hepatitis C after liver transplant. World J Gastroenterol 2014; 20(31): 10668-10681 [PMID: 25152571 DOI: 10.3748/wjg.v20.i31.10668] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
61 Charlton M, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, Mchutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology 2015;148:108-17. [DOI: 10.1053/j.gastro.2014.10.001] [Cited by in Crossref: 274] [Cited by in F6Publishing: 240] [Article Influence: 39.1] [Reference Citation Analysis]
62 Farnik H, Zimmermann T, Herrmann E, Bechstein WO, Kronenberger B, Galle PR, Labocha S, Ferreiros N, Geisslinger G, Zeuzem S, Sarrazin C, Welker MW. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. Liver Int 2015;35:176-83. [PMID: 24649882 DOI: 10.1111/liv.12532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
63 Ikegami T, Yoshizumi T, Soejima Y, Harimoto N, Itoh S, Takeishi K, Uchiyama H, Kawanaka H, Yamashita YI, Tsujita E, Harada N, Oki E, Saeki H, Kimura Y, Shirabe K, Maehara Y. Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: a single-center experience. Transplant Proc 2015;47:730-2. [PMID: 25891720 DOI: 10.1016/j.transproceed.2014.10.058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]